| Bioactivity | Ginsenoside F1, an enzymatically modified derivative of Ginsenoside Rg1, demonstrates competitive inhibition of CYP3A4 activity and weaker inhibition of CYP2D6 activity. | ||||||||||||
| Invitro | Ginsenoside F1 has been shown to flaunt anticancer, anti-aging, and antioxidant effects and has demonstrated competitive inhibition of CYP3A4 activity and weaker inhibition of CYP2D6 activity. The cell viabilities are 68% at the highest concentration of ginsenoside F1 (200 μM) in MTT assays[1]. | ||||||||||||
| Name | Ginsenoside F1 | ||||||||||||
| CAS | 53963-43-2 | ||||||||||||
| Formula | C36H62O9 | ||||||||||||
| Molar Mass | 638.87 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Ginsenoside F1
CAS: 53963-43-2 F: C36H62O9 W: 638.87
Ginsenoside F1, an enzymatically modified derivative of Ginsenoside Rg1, demonstrates competitive inhibition of CYP3A4 a
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.